EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
<iframe src="https://statesidedaily.com/embed/cluster/e9660e9a3634e66e0161f78de911410804aa5f35" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen"></iframe>
